• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Biochem . Immune complexome analysis reveals an autoimmune signature predictive of COVID-19 severity

tetano

Editor, Senior Moderator
Clin Biochem


. 2024 Dec 15:110865.
doi: 10.1016/j.clinbiochem.2024.110865. Online ahead of print. Immune complexome analysis reveals an autoimmune signature predictive of COVID-19 severity

Marino Moriishi[SUP] 1 [/SUP], Takahiro Takazono[SUP] 2 [/SUP], Junya Hashizume[SUP] 3 [/SUP], Nozomi Aibara[SUP] 1 [/SUP], Yuki Jimbayashi Kutsuna[SUP] 4 [/SUP], Masaki Okamoto[SUP] 5 [/SUP], Toyomitsu Sawai[SUP] 6 [/SUP], Teppei Hoshino[SUP] 7 [/SUP], Yusuke Mori[SUP] 7 [/SUP], Yuichi Fukuda[SUP] 8 [/SUP], Yukikazu Awaya[SUP] 9 [/SUP], Hirotomo Yamanashi[SUP] 10 [/SUP], Yuichiro Furusato[SUP] 11 [/SUP], Toyoshi Yanagihara[SUP] 12 [/SUP], Hirotaka Miyamoto[SUP] 13 [/SUP], Kayoko Sato[SUP] 3 [/SUP], Yukinobu Kodama[SUP] 3 [/SUP], Shusaku Mizukami[SUP] 14 [/SUP], Noriho Sakamoto[SUP] 15 [/SUP], Kazuko Yamamoto[SUP] 16 [/SUP], Kei Sakamoto[SUP] 17 [/SUP], Katsunori Yanagihara[SUP] 18 [/SUP], Koichi Izumikawa[SUP] 19 [/SUP], Takahiro Maeda[SUP] 1 [/SUP], Mikiro Nakashima[SUP] 1 [/SUP], Kiyoyasu Fukushima[SUP] 20 [/SUP], Hiroshi Mukae[SUP] 15 [/SUP], Kaname Ohyama[SUP] 21 [/SUP]



Affiliations
Abstract

Background: The factors contributing to the development of severe coronavirus disease 2019 (COVID-19) following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain unclear. Although the presence of immune complexes (ICs), formed between antibodies and their antigens, has been linked to COVID-19 severity, their role requires further investigation, and the antigens within these ICs are yet to be characterized.
Method: Here, a C1q enzyme-liked immunosorbent assay and immune complexome analysis were used to determine IC concentrations and characterize IC antigens, respectively, in the sera of 64 unvaccinated COVID-19 patients with PCR-confirmed SARS-CoV-2 infection, enrolled at seven participating centers in 2020. For the analysis, the patients were split into the severe (n = 35) and non-severe (n = 28) groups on the basis of their COVID-19 symptoms.
Results: We found that neither serum IC concentration nor IC antigen number was associated with COVID-19 severity. However, we identified six IC antigens, which were significantly enriched in the severe versus non-severe group. These IC antigens were all derived from human proteins, namely haptoglobin, the serum amyloid A-2 protein, the serum amyloid A-1 protein, clusterin, and lipopolysaccharide-binding protein, and complement-factor-H-related protein 3. Meanwhile, we found no association between COVID-19 severity and IC antigens derived from SARS-CoV-2 proteins. Collectively, the six IC antigens predicted COVID-19 severity with a moderate degree of accuracy (area under the receiver operating characteristic curve = 0.90, sensitivity = 94 %, specificity = 79 %).
Conclusions: The IC antigen signature identified in this study may have important implications for the diagnosis and treatment of severe COVID-19.

Keywords: COVID-19; Immune complex; Immune complexome analysis; SARS-CoV-2.

 
Back
Top Bottom